WOAH Reference Laboratory Reports Activities 2022

Activities in 2022

This report has been submitted: 8 mars 2023 00:26

Laboratory Information

| Name of disease (or topic) for which you are a designated WOAH Reference Laboratory: | Equine influenza |
| Address of laboratory: | Equine Research Institute, Japan Racing Association 1400-4 Shiba, Shimotsuke Tochigi 329-0412 JAPAN |
| Tel.: | +81-285 44 0090 |
| E-mail address: | manabu_nemoto@jra.go.jp |
| Website: | https://japanracing.jp/en/about/jra_organization/jeri.html |
| Name (including Title) of Head of Laboratory (Responsible Official): | Yoshinori Kasashima DVM, PhD, Director |
| Name (including Title and Position) of WOAH Reference Expert: | Manabu Nemoto DVM, PhD |
| Which of the following defines your laboratory? Check all that apply: | Horse racing authority |

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

| Diagnostic Test | Indicated in WOAH Manual (Yes/No) | Total number of test performed last year
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Indirect diagnostic tests</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemagglutination Inhibition</td>
<td>Yes</td>
<td>12</td>
</tr>
</tbody>
</table>
**TOR2: REFERENCE MATERIAL**

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOAH?
   No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOAH Members?
   Yes

<table>
<thead>
<tr>
<th>TYPE OF REAGENT AVAILABLE</th>
<th>RELATED DIAGNOSTIC TEST</th>
<th>PRODUCED/ PROVIDE</th>
<th>AMOUNT SUPPLIED NATIONALLY (ML, MG)</th>
<th>AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)</th>
<th>NO. OF RECIPIENT WOAH MEMBER COUNTRIES</th>
<th>COUNTRY OF RECIPIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Horse anti-sera against H3N8 equine influenza virus</td>
<td>Haemagglutination inhibition and neutralisation assay</td>
<td>Produced</td>
<td>0</td>
<td>60ml</td>
<td>1</td>
<td>Europe</td>
</tr>
</tbody>
</table>

4. Did your laboratory produce vaccines?
   No

5. Did your laboratory supply vaccines to WOAH Members?
   No

**TOR3: NEW PROCEDURES**

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?
   No

7. Did your laboratory validate diagnostic methods according to WOAH Standards for the designated pathogen or disease?
   No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?
   No

9. Did your laboratory validate vaccines according to WOAH Standards for the designated pathogen or disease?
   No

**TOR4: DIAGNOSTIC TESTING FACILITIES**

10. Did your laboratory carry out diagnostic testing for other WOAH Members?
    No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAH Member?
    No

**TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES**

12. Did your laboratory participate in international scientific studies in collaboration with WOAH Members other than the own?
Yes

<table>
<thead>
<tr>
<th>Title of the study</th>
<th>Duration</th>
<th>PURPOSE OF THE STUDY</th>
<th>PARTNERS (INSTITUTIONS)</th>
<th>WOAH MEMBER COUNTRIES INVOLVED OTHER THAN YOUR COUNTRY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antigenic characterisation of Florida sublineage clade 1 strains</td>
<td>2022-</td>
<td>To evaluate the effectiveness of vaccines against recently circulating Florida sublineage clade strains</td>
<td>- Irish Equine Centre</td>
<td>IRELAND</td>
</tr>
<tr>
<td>Antigenic characterisation of Florida sublineage clade 1 strains</td>
<td>2022-</td>
<td>To evaluate the effectiveness of vaccines against recently circulating Florida sublineage clade strains</td>
<td>- Gluck Equine Research Center, University of Kentucky</td>
<td>UNITED STATES OF AMERICA</td>
</tr>
</tbody>
</table>

**TOR6: EPIZOOLOGICAL DATA**

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

**IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:**

- We performed RT-PCR for equine influenza using nasal swabs collected from febrile racehorses in Japan, and they were all negative.
- We imported recent strains from abroad and performed the antigenic characterisation of recently circulating strains to evaluate the vaccine efficacy.

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

Yes

**IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:**

We submitted the data to the WOAH expert surveillance panel on equine influenza vaccine composition.

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

3


**TOR7: SCIENTIFIC AND TECHNICAL TRAINING**

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAH Members?

No

**TOR8: QUALITY ASSURANCE**

18. Does your laboratory have a Quality Management System?

Yes

<table>
<thead>
<tr>
<th>Quality management system adopted</th>
<th>Certificate scan (PDF, JPG, PNG format)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>L22-702.pdf</td>
</tr>
</tbody>
</table>

19. Is your quality management system accredited?

Yes

<table>
<thead>
<tr>
<th>Test for which your laboratory is accredited</th>
<th>Accreditation body</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemagglutination Inhibition and Conventional RT-PCR</td>
<td>Perry Johnson Laboratory Accreditation (PJLA)</td>
</tr>
</tbody>
</table>

20. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

We have specific laboratories with restricted access. Experiments have been performed and viruses have been stored at specific laboratories with safety cabinets and autoclaves. The application related to biorisk management was submitted to MAFF of Japan to use equine influenza virus for our research and was accepted.

**TOR9: SCIENTIFIC MEETINGS**

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAH?
No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAH?

No

**TOR10: NETWORK WITH WOAH REFERENCE LABORATORIES**

23. Did your laboratory exchange information with other WOAH Reference Laboratories designated for the same pathogen or disease?

Yes

24. Are you a member of a network of WOAH Reference Laboratories designated for the same pathogen?

No

25. Did you organise or participate in inter-laboratory proficiency tests with WOAH Reference Laboratories designated for the same pathogen?

No

26. Did your laboratory collaborate with other WOAH Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

<table>
<thead>
<tr>
<th>TITLE OF THE PROJECT OR CONTRACT</th>
<th>SCOPE</th>
<th>NAME(S) OF RELEVANT WOAH REFERENCE LABORATORIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>WOAH expert surveillance panel on equine influenza vaccine composition</td>
<td>Evaluation of vaccine efficacy against recently circulating strains</td>
<td>- Irish Equine Centre - Gluck Equine Research Center, University of Kentucky</td>
</tr>
</tbody>
</table>

**TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING**

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAH Reference Laboratories for the same pathogen?

Yes

<table>
<thead>
<tr>
<th>Purpose for inter-laboratory test comparisons1</th>
<th>Role of your reference laboratory (organizer/participant)</th>
<th>No. participating laboratories</th>
<th>Region(s) of participating WOAH Member Countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>To check our skills in haemagglutination Inhibition and conventional RT-PCR</td>
<td>Organiser and participant</td>
<td>1</td>
<td>Asia and Pacific</td>
</tr>
</tbody>
</table>

**TOR12: EXPERT CONSULTANTS**

28. Did your laboratory place expert consultants at the disposal of WOAH?

No

29. Additional comments regarding your report:

No